Genomic Valley Biotech Limited (BOM:539206)
India · Delayed Price · Currency is INR 30.40
-0.09 (-0.30%)
At close: Aug 21, 2026
Genomic Valley Biotech Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | - | 0.26 | 0.45 | 0.06 | 0.41 | 0.03 |
Cash & Short-Term Investments | 0.26 | 0.26 | 0.45 | 0.06 | 0.41 | 0.03 |
Cash Growth | -42.01% | -42.01% | 644.62% | -85.30% | 1441.91% | -76.61% |
Accounts Receivable | - | 23.18 | 22.14 | 25.3 | 22.17 | - |
Other Receivables | - | - | - | 0.02 | 0.02 | 0.15 |
Receivables | - | 23.18 | 22.14 | 25.32 | 22.2 | 0.15 |
Inventory | - | 2.84 | 2.84 | - | - | - |
Other Current Assets | - | 0.7 | 0.78 | 3.72 | 3.16 | 11.19 |
Total Current Assets | - | 26.98 | 26.22 | 29.1 | 25.77 | 11.37 |
Property, Plant & Equipment | - | 0.05 | 0.09 | 0.02 | 0.03 | 17.47 |
Long-Term Investments | - | - | - | 0.17 | 4.35 | 4 |
Other Intangible Assets | - | - | - | - | - | 0.08 |
Long-Term Deferred Tax Assets | - | - | - | - | - | 0 |
Other Long-Term Assets | - | 0.05 | 9.05 | 14.05 | 14.05 | 5.05 |
Total Assets | - | 42.5 | 43.57 | 43.34 | 44.2 | 37.97 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | - | 0.06 | 0.1 | 6.02 | 6.11 | - |
Accrued Expenses | - | 0.11 | 0.31 | 0.03 | 1.74 | 0.25 |
Current Income Taxes Payable | - | - | 0.85 | - | - | - |
Other Current Liabilities | - | 3.04 | 3.33 | 1.87 | 1.09 | 1.9 |
Total Current Liabilities | - | 3.21 | 4.58 | 7.91 | 8.93 | 2.14 |
Long-Term Deferred Tax Liabilities | - | 0 | 0.01 | 0 | 0 | - |
Other Long-Term Liabilities | - | - | - | - | - | 7.05 |
Total Liabilities | - | 3.21 | 4.58 | 7.92 | 8.94 | 9.19 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | - | 30.55 | 30.55 | 30.55 | 30.55 | 30.55 |
Retained Earnings | - | - | 5.97 | 2.41 | 2.26 | -4.22 |
Comprehensive Income & Other | - | 8.74 | 2.47 | 2.47 | 2.47 | 2.47 |
Shareholders' Equity | 39.28 | 39.28 | 38.98 | 35.42 | 35.27 | 28.79 |
Total Liabilities & Equity | - | 42.5 | 43.57 | 43.34 | 44.2 | 37.97 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash (Debt) | 0.26 | 0.26 | 0.45 | 0.06 | 0.41 | 0.03 |
Net Cash Growth | -42.01% | -42.01% | 644.62% | -85.30% | 1441.91% | - |
Net Cash Per Share | 0.09 | 0.09 | 0.15 | 0.02 | 0.14 | 0.01 |
Filing Date Shares Outstanding | 2.92 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
Total Common Shares Outstanding | 2.92 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
Working Capital | - | 23.78 | 21.64 | 21.19 | 16.84 | 9.23 |
Book Value Per Share | 12.88 | 12.88 | 12.76 | 11.60 | 11.55 | 9.42 |
Tangible Book Value | 39.28 | 39.28 | 38.98 | 35.42 | 35.27 | 28.71 |
Tangible Book Value Per Share | 12.88 | 12.88 | 12.76 | 11.60 | 11.55 | 9.40 |
Land | - | - | - | - | - | 20.55 |
Machinery | - | - | 0.13 | 0.03 | 2.97 | 3.27 |